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Abstract
Background: MicroRNAs (miRNAs) are small noncoding RNAs that play an important role in the regulation of
various biological processes through their interaction with cellular mRNAs. A significant amount of miRNAs has
been found in extracellular human body fluids (e.g. plasma and serum) and some circulating miRNAs in the blood
have been successfully revealed as biomarkers for diseases including cardiovascular diseases and cancer. Released
miRNAs do not necessarily reflect the abundance of miRNAs in the cell of origin. It is claimed that release of
miRNAs from cells into blood and ductal fluids is selective and that the selection of released miRNAs may correlate
with malignancy. Moreover, miRNAs play a significant role in pharmacogenomics by down-regulating genes that
are important for drug function. In particular, the use of drugs should be taken into consideration while analyzing
plasma miRNA levels as drug treatment. This may impair their employment as biomarkers.
Description: We enriched our manually curated extracellular/circulating microRNAs database, miRandola, by
providing (i) a systematic comparison of expression profiles of cellular and extracellular miRNAs, (ii) a miRNA targets
enrichment analysis procedure, (iii) information on drugs and their effect on miRNA expression, obtained by
applying a natural language processing algorithm to abstracts obtained from PubMed.
Conclusions: This allows users to improve the knowledge about the function, diagnostic potential, and the drug
effects on cellular and circulating miRNAs.
Background
MicroRNAs (miRNAs) are small (~22-nucleotide) non-
coding RNA molecules that are single-stranded in their
functional form and act as post-transcriptional regulators
of gene expression [1]. Their importance was confirmed
in several cellular processes like development, prolifera-
tion, and apoptosis. Moreover, altered miRNA expression
profiles have been linked to a large number of pathologi-
cal conditions, such as cancer, suggesting that miRNAs
are involved in disordered cellular function. miRNA
expression profiles have been shown as potential signa-
tures for the classification, diagnosis, and progression of
cancer [2,3]. Recently, a significant amount of miRNAs
has been found in extracellular human body fluids [4,5].
Some circulating miRNAs in the blood have been suc-
cessfully revealed as biomarkers for several diseases
including cardiovascular diseases, [6] and cancer [4,7].
miRandola is the first comprehensive database of extra-
cellular circulating miRNAs [8]. The database represents a
useful reference tool for anyone investigating the role of
extracellular miRNAs as non-invasive biomarkers as well
as their physiological function and their involvement in
diseases. miRNAs are classified into different categories,
based on their main extracellular forms: complexed with
Argonaute2 (Ago2) proteins [9,10], encapsulated within
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exosomes [11] or bound to high-density lipoprotein (HDL)
[12]. Exosomes are 50-nm to 90-nm vesicles arising from
multivesicular bodies and released by exocytosis [13].
They consist of a limiting lipid bilayer, transmembrane
proteins and a hydrophilic core containing proteins,
mRNAs and miRNAs. Exosomes may horizontally transfer
RNAs, including miRNAs that have been shown to be
functional after exosome mediated delivery [11]. It has
been reported that a significant portion of circulating miR-
NAs in human plasma and serum is associated with Ago2
[9,10]. Ago2 is the effector component of the miRNA-
induced silencing complex (miRISC) that directly binds
miRNAs and mediates messenger RNA repression in cells
[14,15]. The high-density lipoprotein (HDL) is a delivery
vehicle for the return of excess cellular cholesterol to the
liver for excretion. Recently, it has been reported that
HDL transports endogenous miRNAs and delivers them
to recipient cells with functional targeting capabilities [12]
providing evidence that HDL-miRNAs could potentially
serve as novel diagnostic markers in much the same way
exosomal miRNAs have.
This is now emerging as a hot, quickly developing
research topic due to the promising role of extracellular
miRNAs as non-invasive biomarkers. miRandola consti-
tutes a useful environment for the study of reported cir-
culating miRNAs and may help prioritize their systematic
clinical evaluation. Here we present some new tools that
we developed and incorporated into miRandola to help
the discovery of function, diagnostic potential and drug
effects on cellular and extracellular miRNAs in order to
facilitate user investigation of circulating miRNAs.
Content and utility
A database for extracellular miRNAs
miRandola is a comprehensive database of extracellular
circulating miRNAs. It provides a variety of information
including associated diseases, samples, methods used to
isolate miRNAs, the description of the experimental
protocol and the potential biomarker role.
Data is collected from ExoCarta [16], a database of
exosomal proteins, RNA and lipids and PubMed (www.
ncbi.nlm.nih.gov/pubmed/). The database is manually
curated and constantly updated by the authors and the
scientific community who can give its contribution to
the project by submitting new data about extracellular
miRNAs. The current version of the database contains
119 papers, 2276 entries, 590 unique mature miRNAs
and 23 types of samples.
miRNAs are classified into four categories, based on
their extracellular form: miRNA-Ago2 (173 entries),
miRNA-exosome (856 entries), miRNA-HDL (20 entries)
and miRNA-circulating (1227 entries). The latter is used
when information about the specific miRNA carrier is
not available and constitutes the largest group.
The database is implemented in MySQL running on an
Apache server and it is equipped with a PHP web inter-
face. Users may query the database by mature miRNA,
miRNA family, sample, diseases, malignant cell lines, and
potential biomarker role, to get information about the
diseases, processes and functions in which the corre-
sponding miRNAs are involved and the tissues in which
they are expressed. Results consist of published data
about the searched items and predictions computed by
miRo’, a web knowledge base which contains miRNA
functional annotation inferred through their validated
and predicted targets.
A systematic comparison of expression profiles of cellular
and extracellular miRNAs
We extended miRandola with miRNAexpress, the first
tool for the systematic comparison of expression profiles
of cellular and extracellular miRNAs. In three simple steps
(Figure 1) users can compare 1) cellular-cellular miRNA
expression, 2) cellular-extracellular miRNA expression or
3) extracellular-extracellular miRNA expression. First, the
user must specify the miRNA form between cellular and
extracellular, followed by the category of objects to com-
pare among sample, disease and cell lines, miRNA and
drugs. Finally, specific instances of the objects to compare
must be selected, e.g. ‘plasma’ and ‘cancer’. The system
shows the results of the comparison as two lists of up- and
down-regulated miRNAs related to the selected objects.
Cellular miRNA data is taken from PhenomiR [17],
while extracellular miRNA information is obtained from
the miRandola database. The details section (Figure 2)
shows the Disease, Sample and Drug summaries for the
selected miRNA. It contains information on the up- and
down-regulation, the heatmap, links to PubMed, Pheno-
mir and miRandola. Moreover it shows a histogram of
miRNA expression in diseases with up and down regula-
tion. Through miRNAexpress users can observe the
expression profile pattern for each miRNA in a specific
sample or condition. In Figure 1 we report an example of
analysis for hsa-miR-21. In this case, the expression profile
patterns for the cellular and extracellular forms are the
same (upregulation).
In order to infer the effect of drugs on miRNA expres-
sion we downloaded the lists of all miRNAs and drug
names from miRBase [18] and drugbank [19], respec-
tively. For each miRNA, we queried PubMed through the
Entrez utilities [20] in order to retrieve all the papers
whose titles and abstracts contained the name of the
miRNA. We selected the abstracts that contained the
name of the miRNA and the name of a drug. If such
miRNA and drug co-occured in the same sentence, this
sentence was stored as support of the relation miRNA-
Drug. Sentences were extracted from the text by using
the Stanford NLP software [21,22]. We parsed each
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sentence in order to find triples containing subject, verb
and object, where subject and object were either miRNA
or drug names and the verb indicated the effect of the
relationship miRNA-Drug. We performed this task by
using the software ReVerb [23,24]. Next, we manually
parsed the selected data in order to keep only those rela-
tions concerning drugs that are known to up or down
regulate a miRNA, together with the related disease and
the used experimental platform (microarray, Northern
blot, etc.). We enriched our knowledge base by adding
supportive information taken from SM2mir [25], a manu-
ally curated databases which maintains experimentally
validated effects of small molecules on miRNA expres-
sions (last update refers to June 2012). The final results
thus obtained from the above pipeline are presented in
the Drug summary and consist of the PubMed ID of the
paper, the support sentence and, if specified, the related
disease and the experimental techniques.
miRNA targets enrichment analysis
DAVID [26] is a system for gene functional annotation
and enrichment. We now extended miRandola with
miRto, a tool which integrates DAVID functional anno-
tation (through the available web service module [27])
with target prediction (TargetScan www.targetscan.org/
vert_61/ and miRanda www.microrna.org/microrna/
home.do) and validated targets (miRTarbase mirtarbase.
mbc.nctu.edu.tw/) tools.
In the first step users can paste a list of miRNA targets
and in the second step users can set filters for Gene
Ontology terms, KEGG Pathways, number of targets and
p-value. After clicking on the search button two analyses
will be available. The Functional Annotation Clustering
(Figure 3) is based on the hypothesis that similar annota-
tions should share gene members. It integrates a variant
of the Kappa statistics to measure the degree of common
genes between two annotations, and a fuzzy heuristic
Figure 1 miRNAexpress web interface. In the step one users select the miRNA type (cellular or extracellular); in the step two they choose the
sample, disease and cell line, miRNA or drug; in the step three users specify the terms of interest (such as hsa-miR-21). After clicking on the
Compare button users will see the number of up and down regulated miRNAs.
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clustering to classify the groups of similar annotations
according to kappa values. Accordingly, the more com-
mon genes annotations share, the higher chance they will
be grouped together. The p-values associated with each
annotation term inside each cluster are based on Fisher
Exact/EASE Score [28]. The Group Enrichment Score is
used to rank the annotations’ biological significance.
Thus, the top ranked annotation groups most likely have
consistent lower p-values for their annotation members.
The Functional Annotation Chart (Figure 4) is an anno-
tation-term-focused view which lists annotation terms
and their associated genes under study. We report in the
chart the number of miRNAs that bind targets in the spe-
cified user list. After clicking on the count, the system
will show the target prediction for both cellular and
extracellular miRNAs.
Discussion
Circulating miRNAs appear to be affected by various
parameters, including drugs. For instance, De Boer and
colleagues [29] have shown that aspirin intake should be
accounted for when considering circulating miR-126 as
diagnostic biomarker for cardiovascular diseases, or,
more generally, when studying the possible role of miR-
NAs as mediators of cardiovascular disease. Using miR-
NAexpress users can select miR-126 (the specific
miRNA of interest) and discover that aspirin (the related
drug) produces the down-regulation of the miRNA in
patients with type 2 diabetes, thus the use of platelet
inhibitors affect the plasma levels of miR-126 [29]. This
result is showed in Figure 5.
Drugs can also determine the up-regulation of extracel-
lular miRNAs. For instance, by selecting acetaminophen in
miRNAexpress users will see that this drug up-regulates
miR-122 and miR-192 in acetaminophen-induced acute
liver injury (APAP-ALI) providing the evidence for the
potential use of miRNAs as biomarkers of human drug-
induced liver injury [30]. One apparent premise to using
extracellular miRNAs for disease diagnose is the notion
that the abundance of the miRNAs in body fluids reflects
Figure 2 miRNAexpress details section. The details section shows the Disease, Sample and Drug summaries for each selected miRNA with the
number of up and down regulated miRNAs, the heatmap, links to PubMed, Phenomir and miRandola.
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their abundance in the malignant cells causing the disease,
thus researchers have focused on miRNAs that are abun-
dant in the cells of origin.
Using miRNAexpress users can systematically com-
pare cellular and extracellular expression profiles for a
specific disease, and find instead that extracellular
Figure 3 The functional annotation clustering showed using miRto. The functional annotation clustering integrates kappa statistics to
measure the degree of the common genes between two annotations, and fuzzy heuristic clustering to classify the groups of similar annotations
according kappa values.
Figure 4 The functional annotation chart showed using miRto. The functional annotation chart is an annotation-term-focused view which
lists annotation terms and their associated genes under study. We report in the chart the number of miRNAs that bind targets in the user list.
After clicking on the count, users will see the target prediction for both cellular and extracellular miRNAs.
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miRNAs do not necessarily reflect the abundance of
miRNAs in the cell, as demonstrated by recent studies
[31]. For instance, by selecting prostate cancer disease
(in step 3 of the tool), for both extracellular and cellular
miRNAs, users will see that there is no difference in the
expression profile patterns for some miRNAs (e.g. let-
7c, let-7e and miR-107), while there are some differ-
ences for other miRNA signatures (e.g. miR-141 is up-
regulated in the plasma of prostate cancer patients [32],
and is down-regulated in prostate cancer cell lines [33]).
Conclusions
We presented useful tools for further understanding the
role of cellular and extracellular miRNAs in the context
of their targets, regulation and drug effects on their
expressions and annotations. These tools extended the
miRandola database, the only online resource collecting
information about extracellular miRNAs.
Availability and requirements
miRandola is available at http://atlas.dmi.unict.it/
mirandola/
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